Navigation Links
Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
Date:8/22/2013

PITTSBURGH, Aug. 22, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that the company has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) providing bioequivalence study results requested by FDA for Bupropion Hydrochloride (HCl) Extended-release (ER) Tablets USP (XL), 300 mg. Bupropion HCl ER Tablets USP (XL) are the generic version of WELLBUTRIN XL® and are indicated for the treatment of major depressive disorder (MDD).(1) Mylan launched its Bupropion HCl ER Tablets USP (XL), 150 mg and 300 mg, to the U.S. market in September 2010.

In a correspondence issued December 2012, FDA requested all generic drug companies marketing a version of Bupropion HCl ER Tablets, 300 mg, to conduct a fasting bioequivalence (BE) study comparing their Bupropion HCl ER tablets, 300 mg, to GSK's WELLBUTRIN XL (Bupropion Hydrochloride Extended-release) Tablets, 300 mg. In April 2013, Mylan submitted to FDA a sANDA containing the requested study, which demonstrated bioequivalence of Mylan's Bupropion HCl ER Tablets USP (XL), 300 mg, to WELLBUTRIN XL(R) Tablets, 300 mg.

For the 12 months ending June 30, 2013, Bupropion Hydrochloride Extended-release Tablets, 150 mg and 300 mg, had U.S. sales of approximately $503.3 million, according to IMS Health.

Currently, Mylan has 179 ANDAs pending FDA approval representing $84 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $23.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

(1) Patients with a seizure disorder and pediatric patients should not take Bupropion.  Antidepressant medications have been shown to increase the risk of suicide, compared to placebo, in children, adolescents and young adults. Bupropion HCl ER Tablets USP (XL) should not be used for smoking cessation.


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
2. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
3. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
4. Roger Graham Named President of Mylan Specialty
5. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
6. Mylan to Speak at the Goldman Sachs 34th Annual Global Healthcare Conference
7. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
8. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
9. Presenting Sponsor Mylan Specialty L.P. Calls on Communities Nationwide to Join The Food Allergy Research & Education (FARE) Walk for Food Allergy
10. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
11. Deborah Autor, FDAs Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today ... December 31, 2015. The Company also filed its Quarterly Report ... 2016 with the Securities and Exchange Commission today. ... 2015 --> --> Net ... $2.6 million, or 95%, to $5.4 million from $2.8 million ...
(Date:2/11/2016)... , Feb. 11, 2016  Kindred Biosciences, Inc. ... saving and improving the lives of pets, today announced ... of the New Animal Drug Application (NADA) for Zimeta™ ... field study (KB0120) of Zimeta for the control of ... Company. --> --> ...
(Date:2/11/2016)... DUNKIRK, N.Y. , Feb. 11, 2016  Governor ... Athenex that will create 1,400 jobs throughout ... by a partnership with the SUNY Polytechnic Institute, includes ... the Conventus Building in Buffalo , ... square foot manufacturing facility in Dunkirk ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... 13, 2016 , ... With FCPX Overlay Embers from Pixel Film Studios users ... Pro X. Each user can select from up to 40 effect overlays. With FCPX ... offset, hue, saturation, value, contrast, glow, and more all within a click of a ...
(Date:2/13/2016)... ... 13, 2016 , ... In the early or “honeymoon” stage of a relationship, ... out of their way to be romantic, and may exaggerate a strength or two ... online dating profile. , A recent study from Queendom.com , however, suggests ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
(Date:2/12/2016)... , ... February 12, 2016 , ... As a former ... schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn to ... to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice with ...
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured or ... West Penn Burn Center, part of the Allegheny Health Network, has partnered with ... the “Space Heaters Need Space” campaign. , “Space Heaters Need Space” aims ...
Breaking Medicine News(10 mins):